Joseph L. Goldstein - Jan 23, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Joseph L. Goldstein
Stock symbol
REGN
Transactions as of
Jan 23, 2024
Transactions value $
-$878,151
Form type
4
Date filed
1/25/2024, 04:18 PM
Previous filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock +Options Exercise $1,693,499 +2,707 +42.42% $625.60 9,089 Jan 23, 2024 Direct F1
transaction REGN Common Stock -Sell -$2,571,650 -2,707 -29.78% $950.00 6,382 Jan 23, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) -Options Exercise $0 -2,707 -100% $0.00 0 Jan 23, 2024 Common Stock 2,707 $625.60 Direct F1, F2

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on August 24, 2023.
F2 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.